By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


 

Advaxis, Inc. 

The Technology Centre of New Jersey
675 U.S. Route One, South
North Brunswick  New Jersey  08902   U.S.A.
Phone: 732-545-1590 Fax: 732-545-1084


SEARCH JOBS


Industry
Biotechnology






Company News
Gynecologic Oncology Group Phase 2 Study Of Advaxis, Inc.'s Lm-LLO Immunotherapy, ADXS-HPV, For The Treatment Of Persistent Or Recurrent Cervical Cancer Achieves Safety And Efficacy Criteria 1/28/2015 7:55:17 AM
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence First-In-Human Clinical Trials Of ADXS-HER2 1/22/2015 9:25:13 AM
Advaxis, Inc. To Host Analyst & Investor Day On February 3, 2015 1/20/2015 7:52:48 AM
Advaxis, Inc. To Present At The Noble Financial Capital Markets 11th Annual Investor Conference 1/15/2015 7:23:18 AM
Advaxis, Inc. Provides 2014 Year-End Review And 2015 Outlook 1/12/2015 7:38:29 AM
Advaxis, Inc. And The GOG Foundation, Inc. To Collaborate On Global Phase 3 Clinical Trial Of ADXS-HPV In Cervical Cancer 1/7/2015 7:21:02 AM
Advaxis, Inc. Submits Investigational New Drug Application To FDA For ADXS-HER2 1/5/2015 7:05:06 AM
Advaxis, Inc.'s Cancer Immunotherapies Featured On FOX News' Sunday Housecall 12/30/2014 7:33:18 AM
Advaxis, Inc. Completes $17 Million Financing 12/22/2014 7:22:08 AM
Advaxis, Inc. Announces FDA Acceptance Of Its Investigational New Drug Application To Commence Clinical Trials Of ADXS-HPV In Combination With MedImmune (AZN)'s MEDI4736 For The Treatment Of HPV-Associated Cancers 12/15/2014 7:24:48 AM
12345678910...
//-->